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ABSTRACT
Background: Cryptococcus meningitis is the most lethal meningitis in patients with 
HIV/AIDS. It is invariably fatal if not treated appropriately and promptly. In sub-
Saharan Africa with the highest prevalence of HIV/AIDS, response to treatment of 
cryptococcal meningitis has seldom been assessed.
Objective: To describe the clinical features, laboratory findings, CD4+ cell counts and 
clinical outcome after a two-week treatment course of patients having cryptococcal 
meningitis.
Design: Longitudinal, prospective, consecutive entry study.
Setting: Kisumu District Hospital, Nairobi Rheumatology Clinic and Mater hospital 
between July 2001 and May 2007.
Subjects: One hundred and forty one patients with cryptococcus meningitis.
Main outcome measures:CD4+cellcount,cerebrospinalfluid(CSF) biochemistry/
microbiology, morbidity and mortality. 
Results: One hundred and forty one patients (80 males and 61 females) with cryptococcus 
meningitis were included. Mean age and CD4+ cell counts was 36.12 ± 9.1 years (15-
75) and 66.9 ±  102.8 cells/µl (1-1058) respectively. One hundred and forty one (83%) 
patients had CD4 + cell counts <100 cells/µl implying severe immunosuppression. 
Two (1.4%) patients had CD4+ cells > 350 cells/µl and 22 (15.6%) patients had CD4+ 
cell counts between 100-350 cells/µl. Ten (six males and four females) died within one 
week (four amphotericin B, three fluconazole, three no treatment). Eighty one patients 
were simultaneously initiated on HAART.
Conclusion: Cryptococcal meningitis has a good clinical outcome when promptly and 
appropriately managed despite the low CD4+ cell count. Measures to avail amphotericin 
B and fluconazole at the mid level healthcare facilities must be enhanced.
INTRODUCTION
Cryptococcal meningitis is caused by the 
environmental encapsulated fungus, cryptococcus 
neoformans. It is a systemic AIDS defining illness 
and the most common, lethal fungal meningitis 
in patients with human immunodeficiency virus/
acquired immunodeficiency syndrome (HIV/AIDS) 
worldwide. It is common in patients with severe 
immunosuppression and is almost invariably fatal if 
not treated appropriately and promptly (1-7).
 Approximately 7-10% of those infected 
with human immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/AIDS) will 
develop cryptococcal meningitis during the course 
of their illness (8-11).  It is more prevalent in patients 
with CD4+ cell counts lower than 100 cells/µl and 
suffice it to note that cryptococcal meningitis is almost 
always fatal if not treated promptly and appropriately 
(12). Cryptococcus is initially occult in 50% of these 
patients or patients with higher CD4+ cell counts > 300 
cells/µl (9-11).  Poor prognostic indicators in patients 
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with cryptococcal meningitis include positive Indian 
ink test, high cerebrospinal fluid (C.S.F) cryptococcal 
antigen titers, very low C.S.F white cell count (< 20 
white cells/ml), low CSF glucose concentration (< 2 
mmol/L) and high cerebrospinal fluid (CSF) opening 
pressures (> 60 cm H20) (1, 6, 13).  A study done in 
Zimbabwe showed that impaired mental status (GCS 
< 13) and hyponatraemia (Na+ < 130 mmol/L) were 
associated with rapid clinical deterioration (1). 
 It frequently takes more that two weeks for 
drug treatment of cryptococcus meningitis to 
sterilise cerebrospinal fluid (C.S.F), achieve clinical 
improvement and reduce morbidity and mortality. 
Current options for treating cryptococcal meningitis 
include amphotericin B alone, amphotericin B plus 
flucytosine, or fluconazole alone or fluconazole 
after an initial one to two weeks administration of 
amphotericin B.  None of these treatments is entirely 
satisfactory due to low rates of C.S.F sterilisation 
with low dose of amphotericin B, 0.4 mg/kg/day 
(9, 10, 14). This dose is associated with a success 
rate of 40% and mortality rate of 8% at 22 weeks of 
treatment (9,10,14). Intravenous amphotericin B with 
or without flucytocine is usually the standard therapy 
for cryptooccal meningitis in patients with acquired 
immunoideficiency syndrome (AIDS) (14). Ministry 
of health does not always have amphotericin B in its 
kit but occasionally supplies fluconazole. 
 A standard two week induction course of 
amphotericin B deoxycholate (0.7 mg/kg/day) 
and flucytosine 100 mg kg/day is recommended 
(12,16).
 In sub-Saharan Africa few health facilities use 
amphotericin B and ministry of health erratically 
supplies fluconazole. Prompt and appropriate 
treatment is usually associated with good clinical 
outcome and reduced mortality. Longitudinal studies 
evaluating the treatment outcomes of patients with 
cryptococcal meningitis from sub-Saharan Africa are 
scanty yet, it is here where there is the predominant 
global burden of HIV infection.  
 This study was undertaken to define the clinical 
presentation, CD4+ cell count, mode of treatment and 
clinical outcome after two weeks of treatment.  
MATERIALS AND METHODS
Two hundred and fifty one patients (145 males and 
106 females) who had meningitis were examined 
and screened. One hundred and ten (65 males and 45 
females) patients were excluded (Indian ink negative) 
and 141 (80 males and 61 females) patients were 
included in the study. 
 Informed signed consent was obtained from each 
patient, (<18 years old or in coma, signed by parent/ 
guardian).  A standard questionnaire was run for 
each study patient and included; biodata, symptoms 
and signs at presentation. Each study patient 
underwent a thorough clinical examination by one 
of the authors. Diagnostic counselling and testing 
(DCT) (pre- and post- test counselling) was done and 
sustained for each patient. Under aseptic technique, 
blood was taken for complete blood count (CBC), 
CD4+ cell count and ELISA test for HIV. A lumbar 
puncture for cerebrospinal fluid (C.S.F) was also 
performed in every subject after doing a fundoscopy. 
CSF was subjected to microscopy, gram stain, 
biochemistry, acid alcohol fast bacilli (AAFB) smear 
(Ziehl–Nielsen staining) and Indian ink staining. 
C.S.F cryptococcal antigen titer was done for five 
patients who were already on HAART and had severe 
headaches and negative Indian ink test. 
 Only 141 patients (80 males and    61 females) with 
positive Indian ink test, 136 and positive cryptococcal 
antigen test 5, in C.S.F were enrolled for this study. 
This strict inclusion/exclusion criterion could have 
excluded patients with less florid cryptococcal 
meningitis.  Chest X-ray was done at admission 
(if indicated).  HIV serology was confirmed using 
an ELISA test (welcozyme) with a sensitivity and 
specificity of 99.7 and 99.9% respectively. Sera testing 
positive were subjected to ELISA test for confirmation 
of the HIV status. CD4+ cell count was analysed 
using FACS (fluorescent activated cell sorter) flow 
cytometry machine with a sensitivity of 1-2000 cells/
µl (FACS count machine from Baxton, Dickson).  
Ethical Approval: The ethics and standards committee 
Kisumu District Hospital approved the study.
Intervention: Patients diagnosed to have cryptococcal 
meningitis were admitted in the medical wards and 
started on amphotericin B 50mg daily for two weeks. 
Five patients were initiated on intravenous fluconazole 
due to deranged renal functions and could therefore 
not be given amphotericin B. Those who could not 
afford were put on fluconazole (oral or intravenous) 
400 mg daily for two weeks and thereafter, fluconazole 
200 mg daily (patients buy, its erratically supplied by 
the hospital).  Patients were reviewed daily in the 
medical wards till discharge, which was between 
10–31 days depending on their clinical response and 
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co-morbid state.  No post-mortem was performed for 
those who died while on treatment. Convulsions were 
managed using phenytoin sodium or carbamazepine. 
Some patients did not receive anti-fungal treatment 
because fluconazole was out of stock (when they 
were admitted) and they could not afford to buy 
fluconazole or amphotericin B. They only received 
palliative care.
 Eighty one patients could afford to buy HAART 
and were initiated on them. The study was conducted 
when the National Ministry of Health HAART access 
programme was not in place.
Statistical analysis: The data were cleaned and analysed 
using SPSS (version 11). They were expressed as mean 
± SD, tables and bar charts.
RESULTS
One hundred and forty one patients (80 males and 
61 females) were included in the study conducted 
between July 2001 and May 2007.  All the patients 
tested positive for HIV and cryptococcus meningitis 
(136 Indian ink positive, 5, C.S.F cryptococcal antigen 
test positive).
 The mean age range was 36.12 ± 9.1 (15-75) years. 
The mean CD4+ cell count was 66.9 ± 102.8 (1-1058) 
cells/µl. 2 (1.4%) patients had CD4+ cell counts 
> 350 cells/µl, 22 (15.6%) patients had CD4+ cell 
counts of 100-350 and 117 (83%) patients had CD4+ 
cell counts < 100 cells/µl. Ten patients died within 
one week (three no treatment, three fluconazole, and 
two amphotericin B). 
Figure 1
Enrolment profile 
110 excluded (Indian ink negative)
251 patients with meningitis 
examined, screened
44 patients- amphotericin 
B, then fluconazole
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Figure 2
Age distribution of HIV positive patients who had cryptoccocal meningitis
Figure 3
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Table 1
Presenting symptoms of 141 patients with HIV/AIDS and Cryptococcal meningitis. 
Symptom No. (Percentage)
Headache 141 (100)
Neck stiffness 97 (68.8)
Confusion /coma 47(33.3)
Fits (seizure) 92 (65.2)
Fever 70(49.6)
Neurological deficit 10 (7.0)
Blurred vision 27 (19.1)
Table 2
Presenting clinical signs of 141 patients with HIV/AIDS and cryptococcal meningitis 
Sign No (Percentage)
Fever 70 (49.6)
Meningeal signs (stiff neck, Kernig's sign, Brudzinski’s sign) 97 (68.8)
Motor weakness 10 (7.0)
Papilloedema 17 (12.0)
Confusion/coma 47 (33.3)
Cranial nerve palsy 9(6.4)
Table 3
Baseline characteristics
Demographic and laboratory profile of the 141 patients with HIV/AIDS and Cryptococcus meningitis.
Parameter Value
M:F ratio 80:61
Age (years) 36.12 ± 9.1 (15-75)
Mean CD4+ cell count (350-1600 cells/µl) 66.9 ± 102.8 (1-1058)
CD4+ cell counts (cells/µl)
       > 500 2 (1.4% )
       350-499 4 (2.8% )
       200-349 14 (10.0% )





AST (5-40 IU/L) 49.7 ± 17.3 (23-97)
ALT (5-37 IU/L) 37.3 ± 14.2 (21-94)
Creatinine(60-120 µmol/L) 43.9 ± 19.9 (61.3-117.4)
Mean CSF proteins(15-45 mg/L) 166.5 ± 77.3 (311-2570)
Mean CSF glucose (0.83-2.03 mmol/L) 1.9 ± 0.7 (0.1-3.9)
Mean CSF lymphocytes (cells/µl) 6 (0-19)
Drugs used Amphotericin B-44 patients, Fluconazole 94 
patients, No treatment-3 patients.
*CDC-Centres for Disease Control
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DISCUSSION
This study included 141 patients (80 males and 
61 females) with cryptococcal meningitis, 126 of 
whom were highly active anti-retroviral therapy 
(HAART) naïve and 15 were already initiated on 
HAART (5-12 months). The study was conducted 
when HAART and fluconazole were not yet freely 
available and accessible at the public hospitals for 
all patients (supply was erratic, amphotericin B was 
out of supply). The mean age was 36.12 ± 9.1 years 
(15-70). The clinical symptoms and signs all indicated 
meningitis. Cerebrospinal fluid from five patients 
was Indian ink negative and cryptococcal antigen 
titer test positive. Cryptococcal meningitis is the 
most common neurological opportunistic infection 
in HIV/AIDS and almost invariably fatal if poorly 
managed (21, 22).
 Research in Thailand showed that success rates in 
patients treated with 0.4 mg/kg/day of ampthotericin 
B was 40%, with a mortality rate of 8% at two weeks 
(8-10,14). Indeed other studies show that, despite 
the acute mortality rates during initial therapy, 
the 12 month survival rates among all patients on 
maintenance therapy with fluconazole 200 mg daily 
and addition of HAART are significantly improved 
(15,19,20).
 At week two, 40 patients on amphotericin B and 
81 patients on fluconazole were all discharged home. 
Four patients on amphotericin B and six patients on 
fluconazole stayed longer in the hospital for about 
three weeks (six had tuberculosis, four had global 
motor weakness and were undergoing physical 
therapy). Ten (8.8%) died within the first week of 
treatment. Three out of ten were not on anti-fungal 
treatment (Fluconazole was out of stock in the hospital 
and they could not afford to purchase), seven out of 
ten received anti-fungal treatment (3 amphotericin 
B and 4 –intravenous fluconazole). A study done 
in Zambia showed that patients with cryptococcal 
meningitis who did not receive anti-fungal treatment 
were all dead at week seven of follow up (15).
 Only 30 of the discharged patients were followed 
up subsequently. The other 111 patients were not 
followed up for reasons:
(i) Being transferred to other health facilities, which 
had free fluconazole and HAART like Kenyatta 
National Hospital and New Nyanza General 
Hospital Kisumu according to their request.
(ii) Logistics and could not afford transport back 
to the hospital. The follow up of the cohort was 
important since it was noted in Zambia that at 
week 24, most of the patients had died but the 
cause of mortality was not reported (15).
It has been demonstrated that combination therapy 
of amphotericin B and flucytosine was associated 
with a faster clearance of cryptococcus from C.S.F. 
and a better clinical outcome (16). In public hospitals, 
amphotericin B is not regularly supplied and patients 
had to self-purchase.The administration of the drug 
requires hospitalization.
 Poor prognostic indicators associated with 
increased mortality in cryptococcus meningitis 
have been identified as low CD4+ cell count with 
a high visible cryptococcal count at admission of 
> 900 × 103/ml, Glasgow coma scale (GCS) < 13, low 
body weight on admission < 40 kg, higher systolic 
blood pressure >150 mm Hg on admission, a higher 
BUN, higher CSF protein > 45g/L and higher CSF 
opening pressure >60 cmH20 (8,17, 18). 
 The mean CD4+ cell counts of the patients were 
very low 66.9 ± 102.8 cells/µl (range of 1-1058). This 
signifies severe immunosuppression and has been 
associated with a large yeast biomass in the sub-
arachnoid space. This requires prompt, appropriate, 
anti-fungal treatment (12, 19). Twenty one (14.9%) 
patients had co-morbidities (hepatitis B virus 4, 
cholecystitis 3 and pulmonary tuberculosis 14). The 
other 120 (85.1%) patients had cryptococcal meningitis 
alone. Indeed the ten patients who died had very low 
CD4+ cell counts of < 50 cells/µl (1-49). Forty seven 
(33.3%) patients presented with confusion/coma 
with a G.C.S (glass coma scale) between 5-8. These 
are patients who require intravenous medication, 
which are not freely and readily available in public 
health facilities and the Centre for Diseases Control 
(CDC) supplies oral fluconazole to few government 
hospitals with comprehensive care clinics. This may 
increase mortality due to cryptococcal meningitis due 
to the low bioavailability of oral fluconazole.
 Forty seven (33.3%) patients in this cohort 
had confusion/coma. A study done in Tanzania 
showed that low CD4+ cell counts plus coma 
predicts cryptococcal meningitis. Thus, cryptococcal 
meningitis is common among Tanzanian HIV positive 
in-patients presenting with headache and/or altered 
mental status (23).  
 The clinical diagnosis of cryptococcal meningitis 
requires high index of suspicion and the laboratory 
back up must be well equipped to isolate the fungus 
and or the antigen. The hospitals should therefore 
have adequate and appropriate anti-fungal drugs for 
immediate initiation of treatment to reduce mortality 
due to Cryptococcal meningitis. The review by Jowi 
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and a study in Zambia also underscore the necessity 
of early diagnosis, prompt appropriate treatment 
and HAART initiation in managing cryptococcus 
meningitis (15, 22). 
 This requires scaling up and adequate supply of 
amphotericin B and fluconazole in the comprehensive 
care clinics where the majority of patients are 
managed. With the inadequate state of investigation 
capability of the HIV care clinics, it would be necessary 
to carry out a study where high dose intravenous or 
oral fluconazole can be used to treat cryptococcal 
meningitis instead of the nephrotoxic amphotericin 
B in resource constrained settings or in HIV infected 
patients who already have compromised renal 
functions. 
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